BlackRock Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

BlackRock Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.91M	Sell	75,196 -12,519	-14%	-$567K	﹤0.01%	1953
2016 Q3	$4.44M	Buy	87,715 +187	+0.2%	+$9.31K	0.01%	1567
2016 Q2	$3.98M	Sell	87,528 -261,566	-75%	-$12M	0.01%	1602
2016 Q1	$13.8M	Buy	349,094 +6,565	+2%	+$261K	0.02%	743
2015 Q4	$19.4M	Buy	342,529 +16,517	+5%	+$839K	0.02%	590
2015 Q3	$13M	Sell	326,012 -9,504	-3%	-$459K	0.02%	770
2015 Q2	$16M	Buy	335,516 +60,600	+22%	+$2.57M	0.02%	699
2015 Q1	$10.9M	Buy	274,916 +16,862	+7%	+$603K	0.01%	908
2014 Q4	$5.76M	Sell	258,054 -4,526	-2%	-$85.8K	0.01%	1266
2014 Q3	$4.12M	Sell	262,580 -245	-0.1%	-$3.66K	0.01%	1478
2014 Q2	$3.9M	Buy	262,825 +55,078	+27%	+$777K	0.01%	1574
2014 Q1	$3.35M	Buy	207,747 +24,444	+13%	+$418K	﹤0.01%	1681
2013 Q4	$1.71M	Sell	183,303 -5,693	-3%	-$55.6K	﹤0.01%	2136
2013 Q3	$2.14M	Buy	188,996 +11,251	+6%	+$155K	﹤0.01%	1906
2013 Q2	$2.38M	Buy	+177,745	New	+$2.18M	﹤0.01%	1733

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's NBIX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Neurocrine Biosciences (NBIX) stake by 14% in Q4 2016, selling an estimated $567K and leaving 75,196 shares worth $2.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

BlackRock Investment Management first reported a position in NBIX in Q2 2013 and has held it in 15 quarters since. The position peaked at $19.4M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

BlackRock Investment Management held 75,196 shares of Neurocrine Biosciences worth $2.91M as of Q4 2016.
BlackRock Investment Management sold 12,519 Neurocrine Biosciences shares in Q4 2016, an estimated $567K.
Neurocrine Biosciences made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1953 holding.
BlackRock Investment Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Neurocrine Biosciences position peaked at $19.4M in Q4 2015.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.